University of Edinburgh spin-out BIOCAPTIVA secures £1.58m funding and launches its msX liquid biopsy technology in the US to improve cancer diagnostics and research.
The company’s magnetic bead platform aims to remove one of cancer diagnostics’ biggest bottlenecks by simplifying the capture of cell-free DNA from blood samples.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results